Daniel Mackey, MD
Hematology & Oncology · Fort Smith, ARNPI 1407877947
Payments from drug & device makers
Across 377 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$674
- AstraZeneca$557
- Merck$532
- Daiichi Sankyo Inc.$530
- GSK$369
- Novartis$354
- plus $3K from 35 others
What the payments were for
- Food & beverage$5,59393%
- Education$3917%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 48 | $674 |
| AstraZeneca | 30 | $557 |
| Merck | 36 | $532 |
| Daiichi Sankyo Inc. | 27 | $530 |
| GSK | 26 | $369 |
| Novartis | 24 | $354 |
| AbbVie | 22 | $354 |
| Amgen | 22 | $307 |
| Eisai Inc. | 22 | $275 |
| Gilead | 17 | $238 |
| Rigel Pharmaceuticals, Inc. | 13 | $224 |
| E.r. Squibb & Sons, L.L.C. | 11 | $160 |
| Johnson & Johnson(2 entities) | 9 | $153 |
| Array Biopharma Inc | 7 | $136 |
| Tempus AI, Inc | 3 | $127 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $112 |
| EMD Serono, Inc. | 7 | $98 |
| Sumitomo Pharma America, Inc. | 3 | $71 |
| Lilly USA, LLC | 4 | $66 |
| Boehringer Ingelheim | 3 | $52 |
| Astellas Pharma US Inc | 3 | $46 |
| Genentech USA, Inc. | 3 | $46 |
| Seagen Inc. | 3 | $44 |
| Puma Biotechnology, Inc. | 3 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Foundation Medicine, Inc. | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Karyopharm Therapeutics Inc. | 2 | $33 |
| Incyte Corporation | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| CTI Biopharma Corp. | 2 | $29 |
| Beigene USA, Inc. | 2 | $28 |
| Bayer | 1 | $28 |
| Exelixis Inc. | 2 | $26 |
| Sanofi | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
| Bausch Health US, LLC | 1 | $14 |
| Pharmaessentia USA Corporation | 1 | $14 |
| Epizyme, Inc. | 1 | $14 |
| Fortovia Therapeutics, Inc. | 1 | $9 |
How this compares
$5,983 in reported general payments places this provider in the 40th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 43 | $642,695 |
| XtandiEnzalutamide | 35 | $481,334 |
| VenclextaVenetoclax | 39 | $480,371 |
| CabometyxCabozantinib S-Malate | 13 | $474,309 |
| JakafiRuxolitinib Phosphate | 23 | $428,594 |
| ErivedgeVismodegib | 19 | $298,052 |
| VerzenioAbemaciclib | 17 | $292,462 |
| TagrissoOsimertinib Mesylate | 17 | $290,498 |
| CalquenceAcalabrutinib Maleate | 19 | $284,744 |
| Lenalidomide | 22 | $225,259 |
| RevlimidLenalidomide | 16 | $218,759 |
| ErleadaApalutamide | 12 | $181,803 |
| InqoviDecitabine/Cedazuridine | 14 | $109,365 |
| EliquisApixaban | 83 | $46,350 |
| XareltoRivaroxaban | 40 | $27,116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $112 | $642,69543 claims |
| AstraZenecaTagrisso, Calquence | $557 | $575,24236 claims |
| Astellas Pharma US IncXtandi | $46 | $481,33435 claims |
| AbbVieVenclexta | $354 | $480,37139 claims |
| Exelixis Inc.Cabometyx | $26 | $474,30913 claims |
| Incyte CorporationJakafi | $32 | $428,59423 claims |
| Genentech USA, Inc.Erivedge | $46 | $298,05219 claims |
| Lilly USA, LLCVerzenio | $66 | $292,46217 claims |
| Bristol Myers SquibbRevlimid | $15 | $218,75916 claims |
| Johnson & JohnsonErleada, Xarelto | $153 | $208,91952 claims |
| PfizerEliquis | $674 | $46,35083 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 92 hematology & oncology providers in Arkansas.
Other hematology & oncology in Fort Smith
- Isam Abdel-KarimFort Smith$658K
- Humdum DurraniFort Smith$324K
- Narender GorukantiFort Smith$20K
- Tony FlippinFort Smith$18K
- Varant ArzoumanianFort Smith$7K
- Aswanth ReddyFort Smith$5K
- John WellsFort Smith$5K
- Joseph BeckFayetteville$33.8M
- Eric SchaeferFayetteville$5.2M
- Ryan HallLittle Rock$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.